Eagle Pharmaceuticals, Inc. is a biotechnology firm headquartered in New Jersey, dedicated to the development and commercialization of innovative injectable therapies, primarily targeting critical care and oncology. The company possesses a promising pipeline that aims to meet significant unmet medical needs in metabolic disorders and critical care environments, underscoring its commitment to improving medication delivery and therapeutic outcomes. With a strategic emphasis on high-quality solutions and patient-centric approaches, Eagle Pharmaceuticals is well-positioned to make a substantial impact on the evolving U.S. healthcare landscape. Show more

Location: 50 TICE BOULEVARD, WOODCLIFF LAKE, NJ, UNITED STATES, 07677, Woodcliff Lake, NJ, 07677, USA | Website: https://www.eagleus.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

4.535M

52 Wk Range

$0.10 - $3.87

Previous Close

$0.35

Open

$0.33

Volume

5,105

Day Range

$0.25 - $0.33

Enterprise Value

4.535M

Cash

15.35M

Avg Qtr Burn

-126K

Insider Ownership

0.00%

Institutional Own.

55.20%

Qtr Updated

06/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bendeka (Bendamustine hydrochloride) injection Details CLL (Chronic Lymphocytic Leukemia)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vasopressin Details Vasodilary shock	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ryanodex (dantrolene sodium) injectable Details MH (Malignant Hyperthermia)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belrapzo (Bendamustine hydrochloride injection) Details CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intravenous Amisulpride Details Nausea and vomiting	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intravenous Amisulpride Details Nausea and vomiting	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Landiolol Details Supraventricular tachycardia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.